Financial reports
20-F
2023 FY
Annual report (foreign)
13 Mar 24
20-F
2022 FY
Annual report (foreign)
15 Mar 23
20-F
2021 FY
Annual report (foreign)
16 Mar 22
20-F
2020 FY
Annual report (foreign)
15 Mar 21
20-F
2019 FY
Annual report (foreign)
18 Mar 20
20-F
2018 FY
Annual report (foreign)
13 Mar 19
ARS
2006 FY
Annual report to shareholders
21 Mar 07
ARS
2005 FY
Annual report to shareholders
13 Apr 06
ARS
2004 FY
Annual report to shareholders
15 Aug 05
Current reports
6-K
Half-Year Report JANUARY – JUNE 2024
29 Aug 24
6-K
Merger Squeeze-Out of MorphoSys Minority Shareholders Approved at 2024 Annual General Meeting
27 Aug 24
6-K
Current report (foreign)
5 Aug 24
6-K
Current report (foreign)
18 Jul 24
6-K
Publication of an inside information according to Article 17 para. 1 of the Regulation (EU) No. 596/2014
12 Jul 24
6-K
Current report (foreign)
2 Jul 24
6-K
Current report (foreign)
21 Jun 24
6-K
MorphoSys and Novartis Sign Delisting Agreement and Intend to
20 Jun 24
6-K
Publication of an inside information according to Article 17 para. 1 of the Regulation (EU) No. 596/2014
20 Jun 24
6-K
Current report (foreign)
10 Jun 24
Registration and prospectus
SC TO-T/A
Third party tender offer statement (amended)
13 Aug 24
SC 14D9/A
Tender offer solicitation (amended)
7 Aug 24
SC TO-T/A
Third party tender offer statement (amended)
7 Aug 24
SC TO-T/A
Third party tender offer statement (amended)
2 Aug 24
SC TO-T/A
Third party tender offer statement (amended)
1 Aug 24
SC TO-T/A
Third party tender offer statement (amended)
31 Jul 24
SC TO-T/A
Third party tender offer statement (amended)
30 Jul 24
SC TO-T/A
Third party tender offer statement (amended)
29 Jul 24
SC TO-T/A
Third party tender offer statement (amended)
25 Jul 24
25
Voluntary exchange delisting
25 Jul 24
Proxies
No filings
Other
UPLOAD
Letter from SEC
26 Oct 21
CORRESP
Correspondence with SEC
12 Oct 21
UPLOAD
Letter from SEC
15 Sep 21
CT ORDER
Confidential treatment order
19 Apr 18
EFFECT
Notice of effectiveness
18 Apr 18
CERT
Certification of approval for exchange listing
17 Apr 18
CORRESP
Correspondence with SEC
16 Apr 18
CORRESP
Correspondence with SEC
16 Apr 18
CORRESP
Correspondence with SEC
4 Apr 18
UPLOAD
Letter from SEC
2 Apr 18
Ownership
SC 13D/A
NOVARTIS AG
15 Aug 24
SC 13D/A
NOVARTIS AG
21 Jun 24
SC 13D/A
NOVARTIS AG
17 Jun 24
SC 13D/A
NOVARTIS AG
10 Jun 24
SC 13G/A
GOLDMAN SACHS GROUP INC
10 Jun 24
SC 13D/A
NOVARTIS AG
28 May 24
SC 13D
NOVARTIS AG
18 Apr 24
SC 13G
GOLDMAN SACHS GROUP INC
11 Mar 24
SC 13G/A
Kynam Capital Management, LP
8 Mar 24
SC 13G/A
T. Rowe Price Investment Management, Inc.
16 Feb 24